EGFR and glioblastoma: The combination of erlotinib and MLN0128, an mTOR inhibitor, affects p-EGFR, p-AKT, p-ERK, and p-RAS40 levels and as well as CCL2 levels and other pro-inflammatory chemokines, decreasing the infiltration of tumor-associated macrophages and prolonging the survival of GBM mice (Fig. 8H) [156].Poor survival is linked to high expression of PDL-1 and a low CD8+ T cell infiltration.